Caris Life Sciences (CAI) Operating Expenses (2024 - 2026)

Caris Life Sciences' Operating Expenses history runs 3 years deep, the most recent figure standing at $210.9 million for Q1 2026.

• In Q1 2026, Operating Expenses rose 17.9% year-over-year to $210.9 million; the TTM figure through Mar 2026 stood at $798.9 million (up 18.3% YoY), while the FY2025 annual figure was $766.9 million, up 14.57% from the prior year.
• Operating Expenses for Q1 2026 stood at $210.9 million, up from $204.5 million in the prior quarter.
• The five-year high for Operating Expenses was $210.9 million in Q1 2026, with the low at $162.5 million in Q3 2024.
• The 3-year median for Operating Expenses is $181.5 million (2025), against an average of $184.3 million.
• Peak annual rise in Operating Expenses reached 22.47% in 2025, while the deepest fall reached 13.37% in 2025.
• Caris Life Sciences' Operating Expenses stood at $167.0 million in 2024, then climbed by 22.47% to $204.5 million in 2025, then grew by 3.14% to $210.9 million in 2026.
• Business Quant data shows CAI's Operating Expenses at $210.9 million in Q1 2026, $204.5 million in Q4 2025, and $184.2 million in Q3 2025.